Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma October 6, 2026
Results Announced for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Ph 3 EXCALIBER-RRMM Trial in RRMM Patients October 1, 2026
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line RRMM October 1, 2026
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line RRMM October 1, 2026
FDA clears new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol September 22, 2026
Positive Topline Results Announced from Ph 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and PFS in RRMM Patients September 9, 2026
Positive Topline Results Announced from Registrational Ph 2 QUINTESSENTIAL Trial of GPRC5D-Directed CAR T Cell Therapy Arlocabtagene Autoleucel September 9, 2026
First patient dosed in Ph 1 KOALA trial of KMCAR™ T-cell therapy in patients with R/R kappa-restricted multiple myeloma September 2, 2026
European Commission approves TECVAYLI (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma August 25, 2026
FDA Grants Accelerated Approval to ZENBEXUS in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma August 20, 2026
NMPA approves felzartamab (Jingfei) + lenalidomide and dexamethasone for treating multiple myeloma patients who have received at least one prior line of therapy August 20, 2026
TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line R/R multiple myeloma July 28, 2026
FDA Accepts NDA for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma; PDUFA: May 2027 July 15, 2026
FDA approves SC Sarclisa (isatuximab-irfc) Escena + SOC for multiple myeloma patients across all existing indications of Sarclisa IV formulation July 15, 2026
CHMP recommendation advances TECVAYLI (teclistamab) plus daratumumab as a potential standard of care for RRMM June 30, 2026
Sarclisa SQ approved in the EU as the first anticancer treatment administered via an on-body injector June 17, 2026
FDA cleared CTA for LILRB4/CD3 targeting TCE bispecific antibody (6MW5311) for the treatment of AML, CMML, and Multiple Myeloma June 17, 2026
DARZALEX® (daratumumab) injectable approved for administration by patients or caregivers for treatment of multiple myeloma June 2, 2026
CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma May 12, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel May 6, 2026
